Rapport Therapeutics shares fall 22.4% premarket
Rapport Therapeutics shares are down 22.4% premarket amid stock and convertible bond sales.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.